Stockscreener 앱 받기
541.70
5.19%
-29.68
시간 외 거래:
541.70
전일 마감가:
$571.38
열려 있는:
$570
하루 거래량:
945.95K
Relative Volume:
1.66
시가총액:
$23.23B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
19.99
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
+13.93%
1개월 성능:
+10.10%
6개월 성능:
-4.09%
1년 성능:
+22.16%
1일 변동 폭
$541.27
$577.02
1주일 범위
$470.76
$585.79
52주 변동 폭
$409.07
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics Corp Stock (UTHR) Moved Up by 7.26% on Oct 1: What Investors Need To Know - TradingKey
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - TradingView
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet - FinancialContent
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More - Yahoo Finance
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia - Benzinga
Cantor Fitzgerald reiterates United Therapeutics stock rating after patent win - Investing.com
BTIG upgrades United Therapeutics stock rating on legal win - Investing.com
Why is United Therapeutics stock gaining today? - Investing.com
United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling - Mugglehead Investment Magazine
Liquidia Corp. Shares Edge Higher After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today - Yahoo Finance
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia - Yahoo Finance
United Therapeutics (UTHR) Shares Surge 13% After Favorable Pate - GuruFocus
Liquidia Loses Bid to Nix United Therapeutics Lung-Drug Patent - Bloomberg Law News
A Look at United Therapeutics Corp (UTHR) After 12.6% Gain -- GF Value $428.32 vs Price $541.89 - GuruFocus
A CEO’s trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
United Therapeutics jumps 13% on court ruling (UTHR:NASDAQ) - Seeking Alpha
U.S. Markets Finished Mixed Wednesday As United Therapeutics Led, Jabil Lagged - Barron's
LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims - Yahoo Finance
Liquidia slumps after US court rules for United Therapeutics in patent fight - Yahoo Finance
UTHR Stock Jumps As Tyvaso Win And Massive Buyback Fuel Momentum - StocksToTrade
Liquidia shares crater after court rules for United Therapeutics - uk.finance.yahoo.com
Liquidia plunges after court ruling in United Therapeutics patent fight (LQDA:NASDAQ) - Seeking Alpha
United Therapeutics Corp Stock (UTHR) Moved Up by 12.20% on Sep 30: Key Drivers Unveiled - TradingKey
After exercising options, a family trust sold 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts - Yahoo Finance
After exercising stock options, the CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics (UTHR) Falls On Goldman Sell Call, Is It Still 29% Undervalued? - Yahoo Finance
United Therapeutics Corporation (UTHR) stock price, news, quote and history - Yahoo Finance Australia
United Therapeutics chairperson & CEO sells $4.7m in stock By Investing.com - Investing.com South Africa
United Therapeutics chairperson & CEO sells $4.7m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 26 September By Investing.com - Investing.com UK
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
After exercising stock options, the CEO's family trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions - Yahoo Finance
UTHR News | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Why United Therapeutics (UTHR) Shares Are Falling Today - Yahoo Finance
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Look at United Therapeutics Corp (UTHR) After 3.5% Decline -- GF Value $427.97 vs Price $472.21 - GuruFocus
United Therapeutics CEO Rothblatt sells $4.67m in stock after option exercise - Investing.com Nigeria
Form 4 United Therapeutics Corporation For: 24 September - Investing.com India
Form 4 United Therapeutics Corporation For: 24 September By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $4,669,918, According to a Recent SEC Filing - marketscreener.com
After exercising 9,500 options, family trusts sold United Therapeutics (UTHR) shares under a pre-arranged plan. - Stock Titan
United Therapeutics Falls as Goldman Sachs Sets $321 Price Target - citybiz
United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR) - Seeking Alpha
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate - ChartMill
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Oct 01 '26 |
Sale |
564.95 |
8,300 |
4,689,051 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 30 '26 |
Sale |
550.22 |
1,920 |
1,056,425 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 30 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 30 '26 |
Sale |
517.97 |
7,580 |
3,926,177 |
326,363 |
0.80%
자본화:
|
볼륨(24시간):